Lower serum beta-CrossLaps in male cardiac transplant recipients treated without prednisolone

Area of Science:

• Nephrology
• Immunology
• Endocrinology

Background:

• Post-transplantation bone disease is a significant complication following cardiac transplantation.
• Immunosuppressive therapies, particularly those including glucocorticosteroids, are implicated in bone metabolism disruption.

Purpose of the Study:

• To compare bone mineral density and bone turnover markers in male cardiac transplant recipients on different immunosuppressive regimens.
• To evaluate the impact of a glucocorticosteroid-free (steroid-free) immunosuppressive regimen versus triple-drug therapy on bone health.

Main Methods:

• Cross-sectional analysis of male heart transplant recipients in the late post-transplantation period.
• Group A: Cyclosporin A and mycophenolate mofetil (steroid-free). Group B: Triple-drug therapy including glucocorticosteroids.
• Bone mineral density assessed by osteodensitometry; bone turnover markers analyzed, including beta-CrossLaps.

Main Results:

• Osteopenia and osteoporosis were prevalent in both treatment groups.
• Serum beta-CrossLaps levels were significantly lower in the steroid-free group (Group A) compared to the triple-drug therapy group (Group B) (428.3±109.4 vs 661.7±337.0 pg/ml, P<0.05).

Conclusions:

• Glucocorticosteroid-free immunosuppressive therapy in cardiac transplant recipients is associated with reduced markers of bone turnover.
• Lower serum beta-CrossLaps levels in the steroid-free group suggest a potentially lower long-term risk of bone deterioration.